Abstract
Background
Anti-ischaemic effect of A1 adenosine receptor agonists was shown in animal and preclinical studies. The present proof-of-concept study aimed at evaluation of the efficacy and safety of a new adenosine A1 receptor agonist capadenoson in patients with stable angina.
Methods
This was a randomized, double-blind, placebo-controlled, single dose-escalating, multicenter trial comparing the effect of capadenoson at 1, 2.5, 5, 10, and 20 mg versus placebo. For each dose step patients were randomized to receive single doses of either capadenoson or matching placebo in a 5:1 ratio. The primary efficacy variable was the absolute difference in heart rate (HR) at maximum comparable level of workload between baseline and post dose exercise tolerance test at maximum concentration of capadenoson. Capadenoson effect on total exercise time and time to 1-mm ST-segment depression were also measured.
Results
Sixty-two male patients with stable angina were enrolled in the study. There was a consistent trend for HR reduction at comparable maximum work load in active treatment groups, with significant differences against placebo for 10 and 20 mg (HR reduction by 12.2 and 6.8 beats per min, p = 0.0002 and p = 0.032, respectively). A statistically significant trend (p = 0.0003) for a reduction in HR with increasing doses of capadenoson was shown. Increases in total exercise time and time to 1-mm ST-segment depression were also observed.
Conclusions
In patients with stable angina capadenoson lowers exercise HR at comparable maximum workload, which is associated with improved total exercise time and prolongation of time to ischaemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fox K, Garcia MAA, Ardissino D et al (2006) Task force on the management of stable angina pectoris of the European Society of Cardiology. Guidelines for the management of stable angina pectoris. Eur Heart J 27:1341–1381
Borer JS, Fox K, Jaillon PP, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an I f inhibitor, in stable angina. A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107:817–823
Tardif JC, Ford I, Tendera M, Bourassa MG, INITIATIVE Investigators (2005) Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529–2536
Liu Y, Yang X, Yang XM, Walker S, Förster K, Cohen MV, Krieg T, Downey JM (2010) AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts. Basic Res Cardiol 105:129–137
Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol 100:121–126
Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T (2010) Ivabradine with combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol 99:665–672
Hjalmarson A, Gilpin EA, Kjekshus J et al (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65:547–553
Fox K, Ford I, Steg PG, Tendera M, Robertson M, BEAUTIFUL investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817–821
Yan L, Burbiel J, Maass A, Mueller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8:537–576
Belardinelli L, Shryock J, Song Y, Wang D, Srinivas M (1995) Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 9:359–365
Dhalla A, Shryock J, Shreenivas R, Belardinelli L (2003) Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 3:369–385
Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84:350–356
Auchampack JA, Gross GJ (1993) Adenosine A1 receptors, KATP channels and ischaemic preconditioning in dogs. Am J Physiol 264:H1327–H1336
Zablocki JA, Wu L, Shryock J, Belardinelli L (2004) Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation. Curr Top Med Chem 4:839–854
Frey R, Mueck W, Delesen H (2006) Single dose, basic phase I dose-escalation study in a randomized, single-blind, placebo-controlled, group comparison design to investigate safety and tolerability of BAY 68-4986 and its pharmacodynamics and pharmacokinetics after oral dosing in 8 healthy male subjects per dose step. Internal Archive, Report Number PH-34381
Shewan LG, Coats AJ (2010) Ethics in the authorship and publishing of scientific articles. Int J Cardiol 144:1–2
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G (1999) A1 and A3 adenosine receptor agonists: an overview. Exp Opin Ther Patents 9:515–527
Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901–1910
Higgins MJ, Hosseinzadeh H, MacGregor DG, Ogilvy H, Stone TW (1994) Release and actions of adenosine in the central nervous system. Pharm World Sci 16:62–68
Press NJ, Gessi S, Borea PA, Polosa R (2007) Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin Ther Pat 17:979–991
Acknowledgments
The study was funded by Bayer Schering Pharma, Wuppertal, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tendera, M., Gaszewska-Żurek, E., Parma, Z. et al. The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol 101, 585–591 (2012). https://doi.org/10.1007/s00392-012-0430-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-012-0430-8